MLR Maelor

RNS Number:0152P
Maelor PLC
19 July 2005

PRODUCT UPDATE



 Maelor Announces Launch of ContiSol(R) in Canada, and Appointment of Exclusive
                Volplex(R) Distributor in Greece and the Balkans



19 July 2005:  Maelor plc ("Maelor" or the "Company"), the specialist healthcare
products company, today announces the launch of ContiSol in Canada and a new
distribution agreement for Volplex in southeast Europe.



ContiSol



Following the appointment of American Australian Medical, Inc. (AAM) as the
exclusive ContiSol distributor for North America in April 2005, Maelor is
pleased to report that the product has now been launched in Canada.



AAM is a marketer and distributor of specialist urological and pain management
products throughout North America, making them the ideal distribution partner
for ContiSol. Currently the company has 21 dedicated representatives and an
experienced marketing team supporting the sales force.



ContiSol is a range of cleansing solutions designed to prolong the life of
indwelling urethral catheters and to prevent blockages.  By incorporating a
bellows design it gently flushes the catheter, thus reducing the need for
expensive and uncomfortable replacement.  The nurse or patient administering
ContiSol is able to control accurately both the rate and volume of delivery
whilst maintaining the highest possible aseptic standards.  ContiSol is also
available in Spain, Greece and Cyprus, and is distributed in the UK and Ireland
by Bard Limited under their brand name OptiFlo(R).  The product currently has a
46% share of the UK market, which is estimated to be worth in excess of #5
million (source: IMS).



Volplex



Maelor has signed an exclusive distribution agreement with V.I. Pharma
International, SA (VIP) for the sale and marketing of Volplex, Maelor's blood
plasma volume replacement product, in Greece, Cyprus, Albania, Bulgaria,
Croatia, and Romania.



VIP is a company which operates in southeast Europe, and sells a range of
innovative therapeutic and diagnostic products in the haematology and diabetes
fields.  The regulatory dossier has already been submitted by VIP in Greece,
where the company aims to claim a significant share of the growing market,
currently estimated to be around #350,000 annually.



Volplex (succinylated gelatin) is given as an intravenous infusion to substitute
for blood volume lost by patients suffering from the effects of trauma, surgery
or certain medical conditions which result in hypovolaemia (lower than normal
blood volume).  Since launch in 2003, the product has established itself by
winning major contracts in the #8 million UK market through its distributor
Cambridge Laboratories. Volplex has expanded its international franchise,
gaining regulatory approval in Argentina where it will be launched later this
year. In preparation for launch Maelor has established partners in Australia,
Bangladesh, China, South Africa and South Korea.



Stephen Appelbee, CEO of Maelor, said:



"ContiSol is already approved for use in Canada, and AAM can give us immediate
access both to the Canadian market and to local regulatory expertise in the
world's biggest medical products market, the United States.  They are also well
placed to liaise with the University of Alberta, which is currently conducting a
major clinical trial featuring ContiSol.



We are also pleased to welcome VIP as our Volplex distributor in Greece and the
Balkans.  This is a major step in the development of our first pharmaceutical
product, Volplex, as Greece is our first regulatory submission in the European
Union, outside the UK."





For further information:


Maelor plc
Stephen Appelbee, Chief Executive Officer                01978 810153


Financial Dynamics
Ben Atwell/Lucy Briggs                                   0207 831 3113





Notes to Editors:



Maelor plc



Maelor is an AIM-listed specialist healthcare products company, which operates
on a virtual basis, outsourcing both product development and manufacturing. The
company has several products on the market including OptiFlo, ContiSol and
Volplex.



Maelor has various products under development including micelle propofol, a
reformulation of the world's biggest selling general anaesthetic.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCGUUPCMUPAGMR

Maelor (LSE:MLR)
Historical Stock Chart
From Nov 2024 to Dec 2024

Maelor (LSE:MLR)
Historical Stock Chart
From Dec 2023 to Dec 2024